VA-DATAXSTREAM
23.4.2024 15:08:30 CEST | Business Wire | Press release
DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry.
Learn more about DataXstream OMS+ here.
Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization.
Working with DataXstream’s LATAM delivery team, Kötthallen Sorunda, Sweden's leading wholesaler of meat, game, poultry and charcuterie and Fiskhallen Sorunda, the leading sustainable seafood wholesaler in Sweden, were the first two business units to successfully deploy OMS+ across their live networks. The go-live transition went exceptionally smooth, with over 500 orders created on the first day to meet the demand for the next three days.
“The complex nature of Martin & Servera’s sales and order management environment is exactly what OMS+ is built for. They are processing over 15,000 sales order lines a month and can now streamline and automate those processes in a fraction of the time, resulting in faster order entry and a better customer experience. This go-live stands out as one of the best I have ever been part of, thanks to the excellent integration, support and collaboration between Martin & Servera, the systems integrator, DataXstream and the Steering Committee,” said Diego Perelman, President, DataXstream LATAM. “Our move into the Nordic region highlights the continued need among B2B organizations to reduce complexity and streamline sales order processes within SAP SD environments.”
The OMS+ Difference
The ease of deployment across Martin & Servera’s newly installed S/4 HANA backbone is another hallmark of OMS+ as the only platform on the market today that is directly embedded into SAP as a single interface. This allows Martin & Servera to seamlessly align all their companies’ ERPs and applications onto a single platform, reducing complexity and customization, while giving them access to the same real-time master data from SAP and supporting their unique business needs.
As a result, OMS+ will equip Martin & Servera’s sales associates with:
- Real-time visibility into customer history, discounts, and product availability
- Faster manual order entry capabilities
- Access to real-time material characteristics to swiftly find the right materials for customers
- Full sales communications and tracking
Additionally, as OMS+ is embedded into SAP, it aligns perfectly with their roadmap, ensuring that new SAP functionalities are automatically available in OMS+ and the flexibility of its interface will allow Martin & Servera to adjust it easily to their unique requirements.
“We had several challenges associated with this project including an ongoing S/4 implementation that was going on in parallel to the OMS+ deployment,” said Thomas Tolvanen, IT Manager, Grönsakshallen Sorunda AB. “We are incredibly impressed by DataXstream and their professional delivery team. They have been instrumental in the S/4 process design to streamline our processes and complexity. Likewise, their deep knowledge and expertise to identify bugs and errors in customization and master data has been invaluable to us during this process. DataXstream is one of our most valuable partners.”
For additional information, please visit www.dataxstream.com or find us on the SAP store at https://store.sap.com/dcp/en/product/display-0000006561_live_v1
About Martin & Servera
The Martin & Servera group offers goods, services and knowledge for restaurants and commercial kitchens in Sweden. We are a Swedish, family-owned group. Responsible and long-term business is an important part of our business. The Martin & Servera group consists of Martin & Servera Restauranghandel, Martin & Servera Logistics, Martin & Servera Restaurant Shops, Galatea, the Vegetable Hall Sorunda, the Fish Hall Sorunda and the Meat Hall Sorunda.
About DataXstream
DataXstream is an SAP® Gold and Endorsed App Partner dedicated to building solutions on emerging technologies that maximize the ROI of our customers’ SAP® infrastructure. As members of the SAP® marketplace, DataXstream’s products can be found in the SAP® Store. Your company is already running the most powerful ERP solution; empower your employees with DataXstream’s OMS+ to take your organization’s sale and customer buying experience to new levels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423069303/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom